Fig. 5: The clinical implications and mechanisms of the HLA associations with differential spike/RBD antibody levels. | Nature Medicine

Fig. 5: The clinical implications and mechanisms of the HLA associations with differential spike/RBD antibody levels.

From: Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Fig. 5: The clinical implications and mechanisms of the HLA associations with differential spike/RBD antibody levels.

a, AlphaFold-based model of HLA-DQA1:01:02–HLA-DQB1:06:02–spike peptide. The peptide is shown in orange. Residue numbering corresponds to UniProt ID P0DTC2. Memory B cell (b), CD4+ T cell proliferation (c) and AIM CD4+ T cell (d) responses using biologically independent samples from 20 individuals from COV001 and COV002 stratified by carriage of HLA-DQB1*06 allele carriage sampled at days 0 and 84 after first vaccine, with significant differences tested for using a one-sided Wilcoxon rank test. Statistical differences were seen between HLA carriage groups for the memory B cell responses (b, P = 0.05) and S1 proliferation response (c, P = 0.01) at day 84. Box plot center line indicates median; box limits indicate upper and lower quartiles; and whiskers indicate 1.5× IQR. *P < 0.05.

Back to article page